Shengzhi Chang

Shengzhi Chang

Auto-generated profile, based on publicly available information

Shengzhi Chang

Department of Biological Sciences, Sookmyung Women's University, Seoul 04310, Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019
Verified
Journal Article
Open access
CPChoa Park
Choa Park
YLYejin Lee
Yejin Lee
SJSoyeon Je
Soyeon Je
SCShengzhi Chang
Shengzhi Chang
NKNayoung Kim
Nayoung Kim
SYSukjoon Yoon Yoon
Sukjoon Yoon Yoon
Oncogenic gain-of-function mutations are clinical biomarkers for most targeted therapies, as well as represent direct targets for drug treatment. Although loss-of-function mutations involving the tumor suppressor gene, STK11 (LKB1) are important in lung cancer progression, STK11 is not the direct target for anticancer agents. We attempted to identify cancer transcriptome signatures associated with STK11 loss-of-function mutations. Several new sensitive and specific gene expression markers (ENO3, TTC39C, LGALS3, and MAML2) were identified using two orthogonal measures, i.e., fold change and odds ratio analyses of transcriptome data from cell lines and tissue samples. Among the markers identified, the ENO3 gene over-expression was found to be the direct consequence of STK11 loss-of-function. Furthermore, the knockdown of ENO3 expression exhibited selective anticancer effect in STK11 mutant cells compared with STK11 wild type (or recovered) cells. These findings suggest that ENO3-based targeted therapy might be promising for patients with lung cancer harboring STK11 mutations.